Literature DB >> 22114648

Treatment strategies for resistant arterial hypertension.

Felix Mahfoud1, Frank Himmel, Christian Ukena, Heribert Schunkert, Michael Böhm, Joachim Weil.   

Abstract

BACKGROUND: Resistant hypertension is defined as blood pressure above the target range set by current guidelines despite the concurrent use of three or more antihypertensive drugs of different classes, including a diuretic, at their maximum or highest tolerated doses. This problem affects 5% to 15% of all hypertensive patients and is thus commonly seen by both primary care physicians and specialists.
METHODS: Review of current guidelines and pertinent literature revealed by a selective Medline search.
RESULTS: The treatment of resistant hypertension is multimodal, involving systematic identification of secondary causes of hypertension as well as the exclusion of pseudoresistance (inadequate treatment). Non-pharmacological treatment includes weight loss, dietary salt restriction, exercise, and abstinence from alcohol. Drug treatment consists of an individualized combination of antihypertensive agents with different mechanisms of action. Activation of the sympathetic nervous system is considered to be a major element in the pathogenesis of resistant hypertension; a new interventional treatment, selective denervation of the renal sympathetic nerves, results in clinically relevant and sustained blood pressure reduction in ca. 84% of the patients undergoing the procedure (a mean decrease of office systolic blood pressure by 32 mm Hg and by 12 mm Hg at six months, p <0.001). Among the 206 patients who underwent this procedure in the setting of published studies, 5 had complications; these included pseudoaneurysm of the femoral artery and dissection of the renal artery during the introduction of the ablation catheter.
CONCLUSION: The treatment of resistant hypertension is interdisciplinary and multimodal. The new and promising option of interventional renal sympathetic denervation can be considered for patients whose high blood pressure is inadequately controlled with medication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114648      PMCID: PMC3221418          DOI: 10.3238/arztebl.2011.0725

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  24 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

3.  Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.

Authors:  Clara C Chan; Christopher M Reid; Tai-Juan Aw; Danny Liew; Steven Joseph Haas; Henry Krum
Journal:  J Hypertens       Date:  2009-12       Impact factor: 4.844

4.  Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Christian Ukena; Felix Mahfoud; Ingrid Kindermann; Christine Barth; Matthias Lenski; Michael Kindermann; Mathias C Brandt; Uta C Hoppe; Henry Krum; Murray Esler; Paul A Sobotka; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2011-09-06       Impact factor: 24.094

5.  Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists.

Authors:  Martin Thoenes; Ulrich Tebbe; Ludger Rosin; W Dieter Paar; Peter Bramlage; Wilhelm Kirch; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2011-01-05       Impact factor: 5.460

6.  Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.

Authors:  Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

7.  Why is hypertension so frequently uncontrolled in secondary prevention?

Authors:  Jacques Amar; Bernard Chamontin; Nathalie Genes; Christelle Cantet; Michel Salvador; Jean Pierre Cambou
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

8.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

9.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more
  16 in total

1.  A pseudo-quality assurance fig leaf.

Authors:  Akhil Chandra
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

2.  An experimental procedure paid for by the general public.

Authors:  Johannes Mann; Karl Hilgers; Roland Veelken; Friedrich Luft
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

3.  Anxiety as an important factor.

Authors:  Mechthilde Kütemeyer
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

4.  A new procedure, but for whom?

Authors:  Manfred Anlauf; Franz Weber
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

5.  Stress: aspects of endocrine hypertension.

Authors:  Christian A Koch
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

6.  Biased reasoning.

Authors:  Joachim Beige
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

7.  Association of vitamin D status and blood pressure response after renal denervation.

Authors:  Janine Pöss; Felix Mahfoud; Christian Ukena; Murray David Esler; Markus Schlaich; Dagmara Hering; Bodo Cremers; Ulrich Laufs; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2013-10-31       Impact factor: 5.460

8.  [Heart and kidneys. Renal denervation as therapy for hypertension].

Authors:  F Mahfoud; D Linz; M Böhm
Journal:  Herz       Date:  2013-02       Impact factor: 1.443

Review 9.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

10.  Improved heart rate dynamics in patients undergoing percutaneous renal denervation.

Authors:  Frank Himmel; Joachim Weil; Michael Reppel; Kai Mortensen; Klaas Franzen; Leidinger Ansgar; Heribert Schunkert; Frank Bode
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.